Search research articles
Contact Us
Filters
Showing results (41-50 of 51) with videos related to
Page
of 6
Sort By:
European Journal of Medicinal Chemistry
|
February 26, 2017
Design, synthesis, biological evaluation and X-ray structural studies of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole scaffolds
Stefano Sainas, Agnese C Pippione, Marta Giorgis, et al.
European Journal of Medicinal Chemistry
|
December 12, 2018
Hydroxyazole scaffold-based Plasmodium falciparum dihydroorotate dehydrogenase inhibitors: Synthesis, biological evaluation and X-ray structural studies
Agnese C Pippione, Stefano Sainas, Parveen Goyal, et al.
European Journal of Medicinal Chemistry
|
March 19, 2026
Structure-based design of new pyrazole inhibitors targeting Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH)
Agnese C Pippione, Noemi Villella, Federico Fornaseri, et al.
Biomolecules
|
September 28, 2023
Exploring the Potential of Sulfur Moieties in Compounds Inhibiting Steroidogenesis
Tomasz M Wróbel, Katyayani Sharma, Iole Mannella, et al.
Journal of Medicinal Chemistry
|
June 26, 2018
Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors
Stefano Sainas, Agnese C Pippione, Elisa Lupino, et al.
European Journal of Medicinal Chemistry
|
May 12, 2026
Targeting dihydroorotate dehydrogenase (hDHODH) beyond the barrier: discovery of MEDS700 as blood-brain barrier permeable hDHODH inhibitor
Stefano Sainas, Chiara Vigato, Paola Circosta, et al.
Cellular Oncology (Dordrecht, Netherlands)
|
November 19, 2020
AKR1C3 is a biomarker and druggable target for oropharyngeal tumors
Caterina Peraldo-Neia, Paola Ostano, Maurizia Mello-Grand, et al.
Journal of Medicinal Chemistry
|
April 12, 2021
Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-<i>a</i>]pyridine Scaffold: SAR of the Biphenyl Moiety
Stefano Sainas, Marta Giorgis, Paola Circosta, et al.
European Journal of Medicinal Chemistry
|
February 16, 2024
Structure-guided optimization of 3-hydroxybenzoisoxazole derivatives as inhibitors of Aldo-keto reductase 1C3 (AKR1C3) to target prostate cancer
Agnese Chiara Pippione, Sandra Kovachka, Chiara Vigato, et al.
Cell Death & Disease
|
June 30, 2022
Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia
Mohammad Houshmand, Nicoletta Vitale, Francesca Orso, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 51) with videos related to
Sort By:
Page
of 6
European Journal of Medicinal Chemistry
|
February 26, 2017
Design, synthesis, biological evaluation and X-ray structural studies of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole scaffolds
Stefano Sainas, Agnese C Pippione, Marta Giorgis, et al.
European Journal of Medicinal Chemistry
|
December 12, 2018
Hydroxyazole scaffold-based Plasmodium falciparum dihydroorotate dehydrogenase inhibitors: Synthesis, biological evaluation and X-ray structural studies
Agnese C Pippione, Stefano Sainas, Parveen Goyal, et al.
European Journal of Medicinal Chemistry
|
March 19, 2026
Structure-based design of new pyrazole inhibitors targeting Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH)
Agnese C Pippione, Noemi Villella, Federico Fornaseri, et al.
Biomolecules
|
September 28, 2023
Exploring the Potential of Sulfur Moieties in Compounds Inhibiting Steroidogenesis
Tomasz M Wróbel, Katyayani Sharma, Iole Mannella, et al.
Journal of Medicinal Chemistry
|
June 26, 2018
Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors
Stefano Sainas, Agnese C Pippione, Elisa Lupino, et al.
European Journal of Medicinal Chemistry
|
May 12, 2026
Targeting dihydroorotate dehydrogenase (hDHODH) beyond the barrier: discovery of MEDS700 as blood-brain barrier permeable hDHODH inhibitor
Stefano Sainas, Chiara Vigato, Paola Circosta, et al.
Cellular Oncology (Dordrecht, Netherlands)
|
November 19, 2020
AKR1C3 is a biomarker and druggable target for oropharyngeal tumors
Caterina Peraldo-Neia, Paola Ostano, Maurizia Mello-Grand, et al.
Journal of Medicinal Chemistry
|
April 12, 2021
Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-<i>a</i>]pyridine Scaffold: SAR of the Biphenyl Moiety
Stefano Sainas, Marta Giorgis, Paola Circosta, et al.
European Journal of Medicinal Chemistry
|
February 16, 2024
Structure-guided optimization of 3-hydroxybenzoisoxazole derivatives as inhibitors of Aldo-keto reductase 1C3 (AKR1C3) to target prostate cancer
Agnese Chiara Pippione, Sandra Kovachka, Chiara Vigato, et al.
Cell Death & Disease
|
June 30, 2022
Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia
Mohammad Houshmand, Nicoletta Vitale, Francesca Orso, et al.
Page
of 6